{"id":"npc-16-standard-dosing-regimen-group","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL2372276","moleculeType":"Protein","molecularWeight":"1363.59"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to S1PR1, NPC-16 inhibits the egress of lymphocytes from lymphoid organs, thereby reducing inflammation and autoimmune responses. This mechanism is thought to be beneficial in treating autoimmune diseases such as multiple sclerosis.","oneSentence":"NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:25.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT02362711","phase":"PHASE3","title":"Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2015-02","conditions":"Dysmenorrhea","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg"],"phase":"phase_3","status":"active","brandName":"NPC-16 Standard Dosing Regimen Group","genericName":"NPC-16 Standard Dosing Regimen Group","companyName":"Nobelpharma","companyId":"nobelpharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NPC-16 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}